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Purpose: Anisotropy of the 192Ir source causes a lack of dose coverage at the apex in HDR 
vaginal cylinder brachytherapy (VC BT). In this study, we took advantage of the GEANT4 
Monte Carlo (MC) simulation code to design a new DMBT vaginal applicator so that it 
maintains the dose coverage of the current vaginal cylinder at periphery everywhere while 
improving the apex coverage. In addition, since current treatment planning systems (TPS) 
considers the whole environment as water according to TG43 formalism, based on the capability 
of the MC in the calculation of dose in the material, the effect of inhomogeneity of the vaginal 
cylinder in the dose coverage was investigated.  
Methods: The new DMBT vaginal applicator was designed to be a 30 mm diameter, single 
lumen vaginal cylinder, made of polyphenylsulfone (PPSU) plastic. The central part of the 
applicator, which includes the lumen, was considered to be a detachable 8 mm diameter tandem 
rod. In order to provide directional modulation, a tungsten rod similar to the dimensions of the 
detachable tandem was added to the simulation. The applicator works in two steps. First, we get 
a typical dose distribution based on the planning system using the applicator with a detachable 
polyetheretherketone (PEEK) plastic tandem in place. Second, the detachable tandem is replaced 
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with a tungsten tandem to compensate for the lack of coverage at the apex utilizing a directional 
radiation beam generated. The same source dwell positioning is used for both steps, while the 
dwell time for the second step is a small fraction of the first step. Furthermore, in order to assess 
the effect of VC inhomogeneity, a separate simulation with the same dwell time and position 
based on TG43 model was performed and the results were compared.  The MATLAB software 
was used for data analysis. 
Results: The analysis showed that the new applicator can address the lack of coverage at the apex 
due to anisotropy (~2 mm), while simultaneously preventing from overdosing the periphery. 
Also, the analysis of the data indicated that there is a reduction of dose at the surface of the 
cylinder (~7.3%) at the periphery, in comparison to TG43 model.  
Conclusion: This new DMBT concept design can be considered as a possible solution for the 
lack of apex coverage due to anisotropy as there is a subset of patients who experience 
recurrences after brachytherapy, frequently in the vaginal apex. Further, based on the VC 
heterogeneity analysis, the reduction of the dose at the surface of the cylinder indicates that 
prescribing the dose to VC surface involves additional level of uncertainty.  







Endometrial carcinoma is the most common gynecologic malignancy in the united states. It 
constitutes 6% of female cancers, and accounts for 3% of all cancer deaths in women. The 
incidence of endometrial cancer has been steadily increasing in the U.S. and worldwide over the 
past several decades. The standard treatment for endometrial cancer is a total abdominal 
hysterectomy with bilateral salpingo-oophorectomy with or without lymph node dissection. 
Adjuvant external beam radiation therapy (EBRT) and/or brachytherapy (BT) are integral 
component in the adjuvant therapy of select patients and the radiation is a major component in 
the management of inoperable or recurrent endometrial cancers (Alban et al., 2020; Demiral, 
2017; Small et al., 2012). 
The recent clinical trial (PORTEC-2) compared vaginal BT with EBRT in early-stage 
postoperative endometrial cancer patients. The study suggested that vaginal BT is equivalent to 
EBRT in preventing local vaginal recurrences and distant metastases (Nout et al., 2010). Vaginal 
brachytherapy is also associated with significantly less toxicity when compared to whole pelvic 
EBRT (Petereit et al., 1999; Zhang et al., 2016). In addition, High dose-rate (HDR) 
brachytherapy is advantageous in that you can achieve a highly conformal dose to the target 
under image guidance in an outpatient setting (Zhou et al., 2017). Nonetheless, intracavitary BT 
is best reserved for tumors less than 5 mm in thickness (Leung et al., 2019).  
Following surgery, the vaginal canal for most patients is roughly cylindrical, and the American 
Brachytherapy Society (ABS) recommends a properly sized, single-channel vaginal cylinder 
applicator (VC) for BT treatment. The VC is the most common applicator used for high-dose-
rate (HDR) BT and is ideal for patients with a narrow vagina. The region, including the vaginal 
cuff, accounts for about 75% of recurrences in endometrial cancer patients. Therefore, vaginal 
cuff BT is recommended to decrease the risk of recurrence without adding the toxicities 
associated with pelvic radiotherapy (Guy et al., 2019; Kim et al., 2018). Besides the simplicity, 
there are a few limiting factors in the application of VCBT that can result in underdosing the 
target, in particular, at the apex.  
In one study, it is shown that the presence of air gaps around the cylinder can potentially reduce 
mucosal dose. They took advantage of post-insertion CT to detect air gaps for 22 patients and 
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concluded more than two-third of the patients presented air gaps, in particular at the apex 
(Sapienza et al., 2019). Hassouna et al. (Hassouna et al., 2014) has also retrospectively assessed 
the presence of air gap in VCBT. Most of the cases they studied had air gap at periphery, 
indicating the reduction of dose coverage at target. A shortage of the coverage has been studied 
by another group through MRI-based evaluation of vaginal cuff, as well. They figured that suture 
material may be restricting access to the vaginal apex and reduce the dose coverage noticeably at 
vaginal cuff, resulting in underdosing of at-risk vaginal mucosa (Chapman et al., 2016).  
Kim et al.(Kim et al., 2018) studied two different Varian’s VC applicators with the same 
diameter, but different top thickness. They showed there is a relatively high loss of coverage at 
the apex for the applicator with the thicker top. Another issue involves the significant dose 
gradients outside of the cylinders and the variability of the dose falloff relative with the cylinder 
size and dose specification point. The effect of the same prescription dose can be significantly 
different in two cylinders, for example, 2.3- cm and 3.5-cm diameter, and dramatically different 
if prescribed to the cylinder surface vs. 5-mm depth. Thus regardless of treatment regimens, the 
way that physicians prescribe the dose can have different clinical outcomes  (Ager et al., 2019; 
Guy et al., 2019).  
Anisotropy of the source is also an important factor that affects the dose coverage at the 
apex. The dose distribution produced by the HDR 192Ir source is inherently anisotropic due 
to self-absorption by the high-density source core, oblique filtration by the source capsule and 
asymmetric geometry of the source capsule (Sharma et al., 2004), which prevents it from having 
a uniform dose coverage at the apex. This phenomenon more commonly affects single-channel 
applicators, as these are the most widely used vaginal applicators. Although it can be modified 
using multichannel applicators through inverse planning to some extent, this modification can 
cause loss of coverage at the other part of the apex (Bahadur et al., 2014; Sabater et al., 2017).  
Further, the effect of VC inhomogeneity in treatment planning can affect the dose coverage, 
depending on the material, the density, the size, and, the design of the applicator. The current 
standard of practice for brachytherapy absorbed dose calculations relies on the AAPM Task 
Group 43 TG43 formalism. The dosimetry parameters used in TG- 43 are obtained for a single 
BT source located at the center of a fixed-volume, homogeneous, liquid-water phantom. As a 
8 
 
result, this method cannot consider the effect of patients’ body shape and the presence of 
materials other than water, such as VCs (Abe et al., 2018; Mikell et al., 2012; Rivard et al., 2004, 
2009). 
In this research, we aim to find a novel solution to remedy the anisotropy of the source for a 
single channel VC applicator, so that it does not affect the integrity of dose distribution of a 
typical VC while eradicating the anisotropy effect. To do this, we benefit from the concept of 
direction modulated brachytherapy (DMBT), which has been used for the design of other 
applicators such as cervical, and rectal applicators by other researchers (Bellezzo et al., 2018; 
Safigholi et al., 2017). The DMBT applicators utilize a shielded part embedded into them in 
order to focus the radiation in a specific direction, while cut the radiation drastically in other 
directions simultaneously. Therefore, we design a novel DMBT vaginal cylinder applicator using 
the general-purpose GEANT4 Monte Carlo (MC) Simulation code to address the anisotropy of 
the source. MC simulation, as gold standard for dosimetry, has been utilized for modeling of the 
brachytherapy sources and evaluation of model-based dose calculation algorithms, considering 
the effect of inhomogeneity on dose calculation, and dose calculation near the source by other 
researchers (Ababneh et al., 2014; Facundo Ballester et al., 2015; Rodrigues et al., 2008). It can 
also account for the limitations  related to TG43 with better accuracy for absorbed dose 
calculations (Mikell & Mourtada, 2010); therefore, as a second goal, we will assess the effect of 
inhomogeneity of VC in the dose coverage and its possible impact on the clinical outcome.  
Material and Method 
The GEANT4 MC simulation code, toolkit 10.05 was used for the simulation. A typical Varian 
Gamma Med Plus source was modeled as described in the literature (Figure 1) (Perez-Calatayud 
et al., 2012). The extension of cable was modeled to be 50 mm. Because of the symmetry, 2D 
data acquisition was performed, such that the source and the extension of the cable were placed 
across the Y axis. The 192Ir was defined based on all its significant gamma-ray and x-ray 
radiations (Ababneh et al., 2014; Chu et al., 1999; X-ray and Gamma-ray Decay Data Standards 




Figure 1. a typical structure for Varian HDR source, Gamma Med Plus 
Calculation of the Dose Rate Constant  
At the first step, Air Kerma Strength (Sk) was calculated. For this purpose, the source was placed 
at the center of a 6*6*6 m3 box, filled with air and gridded into voxels with a 5 mm length side. 
Up to 2 * 1010 histories were performed (F. Ballester et al., 1997).  
At the next step, the source was located at the center of a water phantom 30*30*30 cc, gridded 
into voxels with a length side of 0.5 mm. Up to 5 * 109 histories were performed. As pointed out 
by Williamson (Williamson JF, 1995), air-kerma estimation was found to be well described by 
the linear equation kair /G=Sk +b*y. The slope b describes the increase in kair /G due to buildup of 
scatter in the air and the intercept is an estimate of the ratio of the air-kerma rate in free space 
and the geometry factor.  
Design of the applicator  
The new DMBT vaginal applicator was designed to be a 30 mm diameter, single lumen VC, 
made of PPSU plastic (currently used in Varian’s VC applicators) , with a density of 1.29 g/cm3 
(Sigma-Aldrich, n.d.). The central part of the applicator which includes the lumen was 
considered to be a detachable 8 mm diameter tandem rod. In order to provide directional 
modulation, a tungsten rod similar to the dimensions of the detachable tandem was added to 
simulation. The applicator works in two steps. First, we get a typical dose distribution based on 
the planning system using the applicator with a detachable PEEK (currently used in Varian’s VC 
applicators) tandem, with a density of 1.3 g/cm3, in place. Second, the detachable tandem is 
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replaced with a tungsten tandem, with a density of 19.3 g/cm3, to compensate for lack of 
coverage at the apex utilizing directional radiation beam generated. The same source dwell 
positioning is used for both steps, fed from Varian’s TPS, while the dwell time for the second 
step is equivalent to three quarter of one fraction of the first step (five fractions). For both steps, 
the applicator is placed at a water phantom 30*30*30 cc, gridded into voxels with a side length 
of 1 mm. In addition, because the dwell time and positions were fed from a TG43-based TPS 
(Table 1), the source was placed at the same condition into a water phantom in order to assess 
the effect of the VC inhomogeneity in comparison to TG43 model. The treatment length for this 
plan was 5 cm, while prescribing to 5 mm depth. Up to 109 histories were performed for each 
dwell position. Furthermore, The MATLAB software was used for data analysis.  
 
DP (mm) DT (s) 








Table 1, The data obtained from a TG43 TPS.  Dwell Positions (DP) across the Y Axis and the Dwell Time (DT) of the source were 
used for performing the GEANT4 MC simulations.  
 
Results 




Figure 2, the source and the two-step applicator, designed using GEANT4 MC simulation code. The left, the simulated source. 
The middle, the applicator with the PEEK tandem. The right, the applicator with the Tungsten tandem. (the images are not in 
scale) 
 
The dose rate constant for Gamma Med Plus calculated from the linear fit was obtained to be 
1.122 cGy.h-1.U-1 that is in a good agreement with the consensus data of 1.117 cGy.h-1U-1, with 
relative error less than 0.5% (F. Ballester et al., 2001; Perez-Calatayud et al., 2012).  
 
 
Figure 3, the linear fit for calculation of the air kerma strength 
 


































A typical dose distribution of the Gamma Med Plus source in the water phantom is given in 
Figure 4. 
 
Figure 4, the dose distribution (%) of Gamma Med Plus Source is a water phantom normalized to the dose value at the point 
(10,0) 
 
The results from positioning of the source in the VC applicator with PEEK tandem in place, and 
those from TG43 is given in the Figure 5. The prescription dose line is shown in red. As 
mentioned, the TG43 model does not account for the inhomogeneity of the VC, assuming all the 
environment as water as opposed to the MC calculations. Based on the results, the dose 
distribution inside the cylinder ( -15 mm < x < 15 mm) is noticeably different from TG43 Model, 
so that unlike TG43 Model, the isodose lines 6000 cGy and 4500 cGy cover a larger area inside 





Figure 5, isodose lines (cGy) obtained from GEANT4 MC simulations for TG43 model, considering all the environment as water 
(Left), and for a 30 mm diameter cylinder, considering the inhomogeneity of the VC applicator (Right). The Prescription dose 
line is shown in red. 
 
In addition, the isodose lines slightly shrink at the periphery beyond the VC surface, indicating a 
reduction in the dose coverage. In further investigation, a point by point dose analysis at the 
boundary of the applicator and water phantom was also performed across the horizontal line y= 
50 mm with an interval of 1 mm. The dose values are given in the Table 2. Because the point 
x=15 mm is located right at the boundary of the applicator and water phantom, the dose at this 





11 12 13 14 15 16 17 18 19 20 
TG43 Dose 
(cGy) 
4250.81 4041.24 3754.78 3601.63 3364.25 3192.67 3079.86 2815.44 2710.27 2540.59 
VC* Dose 
(cGy) 
3959.28 3741.48 3587.04 3276.63 3118.30 3103.05 2925.12 2763.68 2658.72 2466.86 
* Vaginal Cylinder 
Table 2, Dose per Point at y=50 mm obtained from GEANT4 MC simulations, for TG43 Model (without considering the effect of 
VC heterogeneity) as well as a 30 mm diameter VC applicator (with considering the effect of VC heterogeneity) 
Comparing the data at the surface of the cylinder (x = 15 mm) indicates that there is a reduction 
of 7.3% in dose at the boundary for the VC compared to TG43 (3118.30 vs 3364.25 cGy), 
resulting in a cold spot at the surface.  
For better analysis, the dose data for the applicator were also categorized into 2 groups and an 
exponential function was fitted for each set of data, as given. 
 
 






































































As depicted, the attenuation coefficient of the radiation in the water phantom is 0.057 mm-1. 
However, when the applicator is in place, the radiation gets attenuated with the coefficients of 
0.061 mm-1 inside the applicator, and 0.052 mm-1 outside the applicator in the water phantom. 
The multiplication factor for attenuation in the applicator is about 2.3% less than that in the 
water phantom, as well. 
The coverage at the apex looks pretty similar in both models at the prescription isodose line (red 
lines). However, the same type of analysis is given across the horizontal line x=0.  The dose 




74 75 76 77 78 79 80 81 82 83 
TG43 Dose 
(cGy) 
14581.54 9986.77 7281.08 5632.91 4610.98 3769.89 3154.48 2762.90 2371.04 2123.75 
VC* Dose 
(cGy) 
14719.43 9639.88 7270.68 5955.89 4773.11 3973.22 3380.43 2951.93 2569.11 2283.10 
* Vaginal Cylinder 
Table 3, Dose per Point at x=0 mm obtained from GEANT4 MC simulations, for TG43 Model (without considering the effect of VC 
heterogeneity) as well as a 30 mm diameter VC applicator (with considering the effect of VC heterogeneity) 
 
The boundary at the apex is located at y = 76.5 mm. Comparing the dose values at y = 76 mm in 
the two models indicates similar results near the apex surface of the applicator (7281.08 vs 
7270.68 cGy). However, according to the Table 3 there is an average  increase of 5% in dose 
values beyond the boundary (y = 76.5 mm) across the line in the water phantom. 
Furthermore, the results from the two-step DMBT applicator is shown in Figure 9. The 
prescription dose line is shown in red. According to the results, this novel DMBT applicator can 
remove the anisotropy dip at the apex and lift up the prescription isodose line up to 2 mm 
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without overdosing the other periphery surfaces, i.e., only 3-4 % increase in dose at those 
surfaces.  
 
Figure 9, isodose lines (cGy) obtained from GEANT4 MC simulations considering heterogeneities, for a 30 mm diameter 





Discussion and Conclusion   
It is important to generate a radiation dose distribution that best and uniformly conforms to the 
vaginal cuff region as it is the most common place for post-treatment recurrence, through 
optimization during treatment planning. The most recent ABS recommendations (released in 
2012 (Small et al., 2012)), define optimization as the manipulation of the HDR BT dwell 
positions, dwell times, or both. The ABS recommends using an optimization line at the upper 
apex or at vaginal cuff as well as the lateral sides of the applicator to avoid unacceptably high 
doses to the vaginal apex and any overlying portions of the small bowel. Delivering radiation 
dose to the vaginal cuff area that receives uniform prescription dose (Rx) as much as possible is 
desired. At minimum, considerable cold spots should be avoided during the planning process as 
the risk of recurrence at the vaginal cuff site is approximately 70% [9,10]. Due to the nature of 
the source construction, however, the anisotropy of the source will cause underdosage in the 
apex area even after the optimization. 
A novel single-channel DMBT vaginal applicator is proposed in this research to address the 
anisotropy underdosage effect. Based on the results, this applicator can be a possible solution to 
compensate for the lack of coverage at the apex due to anisotropy of the source. With the same 
dwell positions, the dwell times of the source for this compensation was obtained to be a small 
fraction of the total treatment time, i.e., adding few minutes extra to the overall treatment time. 
There is a subset of patients who experience recurrence of the disease at the vaginal apex after 
vaginal BT. Considering an optimization line as ABS recommends and using the new introduced 
DMBT applicator can assure the sufficient coverage of vaginal apex, without overdosing the 
lateral periphery. In addition, the new design can be utilized for minimizing of the underdose 
effect of the frequent air gaps due to the presence of restricting suture materials at the cuff 
through the optimization processes.  
The impact of the cylinder applicator heterogeneity was also investigated in this research. It was 
shown the inhomogeneity of the cylinder (i.e., density being greater than water) could cause the 
creation of cold spot at the surface of the cylinder at the periphery. The main reason for this 
phenomenon is the higher density of the VC than water (1.29 g/cm3), which causes gamma and x 
rays with lower energies to have more interactions inside the applicator as opposed to when 
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TG43 model is assumed with water everywhere. As a result, the applicator has more absorbed 
dose in shallower depth in comparison to when the water is in place. This clarifies why at the 
same depth inside the VC including the surface, there is less dose compared to TG43 model. In 
addition, radiation gets hardened slightly after passing through the higher density applicator, 
which explains the difference among the attenuation coefficients found. The magnitude of cold 
spots is strongly dependent on the size of the cylinder for the same plan (with larger the cylinder, 
e.g., 35 mm, the bigger the effect), since such determines the level of the beam hardening and 
requires further MC simulation studies to characterize.  
The magnitude of anisotropy at the apex is slightly different in the two dose calculation models, 
as well. This is because of the presence of the lumen at the center of the VC applicator. Since the 
channel is not filled with the applicator material (but rather with air), there is no major 
interaction and therefore attenuation inside it. Consequently, the dose increases at the apex of the 
applicator as opposed to the TG43 model predictions. Moreover, the magnitude of the anisotropy 
dip can vary depending on the cylinder top thickness, the material, and the density of the 
applicator, which needs further MC simulation studies to characterize. 
In conclusion, the novel DMBT cylinder design proposed in this thesis work is a potential 
solution to remedy the underdosage at the vaginal apex due to source anisotropy. Such design 
may be of clinical benefit. Also, the VC heterogeneity analysis of this research based on MC 
simulation calculations indicates that prescribing to the VC surface suffers from extra level of 
uncertainty because of the dose reduction at the surface (i.e., cold spots), which should be 
considered in treatment planning.  
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